David Planchard
Inserm · 951 works · 52,560 citations · h-index 89
Top works
- Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
- Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
- Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
- Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer
- Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
- Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component
- Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer
- Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer
- Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
- Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
- EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients
- Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease
- Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC
- Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients